Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Animal Health, Inc. (Jaguar) on October 8, 2015, regarding events occurring on that date. The company is incorporated in Delaware and maintains its principal executive offices in San Francisco, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a material definitive agreement rather than financial performance results.
Material Changes and Agreements
On October 8, 2015, Jaguar entered into a formulation development and manufacturing agreement with Patheon Pharmaceuticals Inc., a wholly owned subsidiary of Patheon Inc. Key terms include:
- Scope: Patheon will provide crofelemer tablets for Jaguar for use in animals.
- Duration: The estimated duration of the agreement is up to 36 months.
- Provisions: The agreement covers manufacturing specifications, forecasting, ordering, delivery, payment terms, confidentiality, and indemnification.
- Disclosure: A press release announcing the agreement was issued on October 15, 2015. The full text of the agreement will be filed as an exhibit to the 2015 Form 10-K, with certain portions subject to a request for confidential treatment.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, outlook, or management commentary regarding future performance. The primary risk noted is that the description of the agreement is qualified by reference to the full text, which includes confidential portions not currently disclosed.
Investor Verification Checklist
- Verify the full text of the manufacturing agreement once filed as an exhibit to the 2015 Form 10-K.
- Review the press release dated October 15, 2015 (Exhibit 99.1) for additional strategic context.
- Monitor future filings for details on the confidential portions of the agreement.
- Confirm the impact of this manufacturing partnership on Jaguar's supply chain and cost structure in upcoming quarterly reports.